Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen to $311 from $331 and keeps an Overweight rating on the shares. The firm models Q2 U.S. Leqembi sales of $38M, versus the Visible Alpha U.S. consensus forecast of $30M, and also adjusted pipeline estimates, the analyst tells investors in a Q2 earnings preview note for the Biopharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: